Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021

Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021 | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021 Pankit Vachhani, Sachi Singhal, Rahul Mishra, Sankalp Arora, Noha Sharafeldin, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9510524/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 10 You are reading this latest preprint version Abstract Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Result (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950/3, essential thrombocythemia (ET) 9962/3, primary myelofibrosis (PMF) 9961/3, and chronic myeloid leukemia (CML) 9875/3] during the years 2000 to 2021. Data of 63,242 (ET, n=24 172; PV, n= 23 456; PMF, n=6 131; CML, n=9 483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100 000 person-years respectively. The incidence of ET, PV, and MF increased with age, and majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML. Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist were noted in our study Biological sciences/Cancer/Haematological cancer/Myeloproliferative disease Health sciences/Medical research epidemiology myelofibrosis polycythemia vera essential thrombocythemia CML PMF ET PV Full Text Additional Declarations There is NO conflict of interest to disclose. Supplementary Files SupplementaryfinalsubmissionSSPV1.pdf Supplementary Figures and Tables TablesandfiguresformainmanuscriptfinalsubmissionSSPV.docx Tables and Figures for main manuscript Cite Share Download PDF Status: Under Review Version 1 posted Review # 1 received at journal 13 May, 2026 Review # 3 received at journal 06 May, 2026 Reviewer # 3 agreed at journal 02 May, 2026 Reviewer # 2 agreed at journal 29 Apr, 2026 Reviewer # 1 agreed at journal 28 Apr, 2026 Reviewers invited by journal 28 Apr, 2026 Editor assigned by journal 27 Apr, 2026 Submission checks completed at journal 27 Apr, 2026 First submitted to journal 27 Apr, 2026 Unknown event 24 Apr, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9510524","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":630854688,"identity":"3107336e-364a-4b0a-b249-ee8cf583fcd8","order_by":0,"name":"Pankit Vachhani","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIiWNgGAWjYJACZsYGBgY29gYGZgg/gVgtPAdI1cIgkUCkFnOJ5IefC3fY5fFJvjH8XJhjx8DPnmOAV4vljDRj6ZlnkovZpHOAjG3JDJI9b/BrMThzwIyZt405sU06x0Cad9sBBoMbBGwxOHP8G1BLfWKb5Bnj3yAt9gS1HO8B2XI4sU2CxwxiiwQhv7T3FEvzth1PbONJK7MG+oVH4syzArxazJnZN37mbatOnN9+ePPtwm12cvztyRvwOwxdgAevcqxaRsEoGAWjYBRgAAAjYkDRFX0ovAAAAABJRU5ErkJggg==","orcid":"","institution":"O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham","correspondingAuthor":true,"prefix":"","firstName":"Pankit","middleName":"","lastName":"Vachhani","suffix":""},{"id":630854689,"identity":"c3afe0ac-4daf-4349-94ae-7a49f7626306","order_by":1,"name":"Sachi Singhal","email":"","orcid":"https://orcid.org/0000-0003-0114-8130","institution":"Fox Chase Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Sachi","middleName":"","lastName":"Singhal","suffix":""},{"id":630854690,"identity":"497948a5-cced-4b2d-a094-68b086befa89","order_by":2,"name":"Rahul Mishra","email":"","orcid":"","institution":"Anne Arundel Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Rahul","middleName":"","lastName":"Mishra","suffix":""},{"id":630854691,"identity":"5b427af7-cc32-4b60-b3e7-cd7945614019","order_by":3,"name":"Sankalp Arora","email":"","orcid":"","institution":"UT MD Anderson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Sankalp","middleName":"","lastName":"Arora","suffix":""},{"id":630854692,"identity":"1979e289-b47a-4bad-992b-9a68ddda5705","order_by":4,"name":"Noha Sharafeldin","email":"","orcid":"https://orcid.org/0000-0001-8835-8899","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Noha","middleName":"","lastName":"Sharafeldin","suffix":""},{"id":630854693,"identity":"f5165688-1138-48c7-9b52-be33a1ac3b2d","order_by":5,"name":"Ruchi Desai","email":"","orcid":"","institution":"Virginia Commonwealth University","correspondingAuthor":false,"prefix":"","firstName":"Ruchi","middleName":"","lastName":"Desai","suffix":""},{"id":630854694,"identity":"043f564e-a6d9-42c0-a57d-0923a0608f48","order_by":6,"name":"Tania Jain","email":"","orcid":"https://orcid.org/0000-0001-6854-773X","institution":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University","correspondingAuthor":false,"prefix":"","firstName":"Tania","middleName":"","lastName":"Jain","suffix":""}],"badges":[],"createdAt":"2026-04-23 21:35:07","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-9510524/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9510524/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":108805057,"identity":"521122da-a696-4ed6-849d-653dee8ae5fe","added_by":"auto","created_at":"2026-05-08 15:24:39","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":649737,"visible":true,"origin":"","legend":"","description":"","filename":"ManuscriptwithcitationsLeukemiaversion.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9510524/v1_covered_260c6ad1-c47e-4151-abab-4a69ea3ac0e0.pdf"},{"id":108594109,"identity":"6994d019-86a9-416a-b373-8e99ac5c3b7a","added_by":"auto","created_at":"2026-05-06 10:14:19","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":2774564,"visible":true,"origin":"","legend":"Supplementary Figures and Tables","description":"","filename":"SupplementaryfinalsubmissionSSPV1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9510524/v1/39a13750aad09d2f4d723e4e.pdf"},{"id":108594110,"identity":"cd0ae7c2-f0df-49c0-8955-206cc2c397c7","added_by":"auto","created_at":"2026-05-06 10:14:19","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":1091352,"visible":true,"origin":"","legend":"Tables and Figures for main manuscript","description":"","filename":"TablesandfiguresformainmanuscriptfinalsubmissionSSPV.docx","url":"https://assets-eu.researchsquare.com/files/rs-9510524/v1/6c5d2291456c95d3c8c6d6fd.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"leukemia","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"leu","sideBox":"Learn more about [Leukemia](http://www.nature.com/leu/)","snPcode":"41375","submissionUrl":"https://mts-leu.nature.com/cgi-bin/main.plex","title":"Leukemia","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"epidemiology, myelofibrosis, polycythemia vera, essential thrombocythemia, CML, PMF, ET, PV","lastPublishedDoi":"10.21203/rs.3.rs-9510524/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9510524/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Result (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950/3, essential thrombocythemia (ET) 9962/3, primary myelofibrosis (PMF) 9961/3, and chronic myeloid leukemia (CML) 9875/3] during the years 2000 to 2021. Data of 63,242 (ET, n=24 172; PV, n= 23 456; PMF, n=6 131; CML, n=9 483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100 000 person-years respectively. The incidence of ET, PV, and MF increased with age, and majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML. Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist were noted in our study","manuscriptTitle":"Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-05-06 10:14:11","doi":"10.21203/rs.3.rs-9510524/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorInvitedReview","content":"This content is not available.","date":"2026-05-13T10:08:02+00:00","index":1,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2026-05-06T08:02:23+00:00","index":3,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2026-05-02T08:32:39+00:00","index":3,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2026-04-29T06:24:02+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2026-04-28T07:50:50+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2026-04-28T07:48:24+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-04-27T15:51:40+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-04-27T15:51:23+00:00","index":"","fulltext":""},{"type":"submitted","content":"Leukemia","date":"2026-04-27T14:31:04+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2026-04-24T14:25:36+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"leukemia","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"leu","sideBox":"Learn more about [Leukemia](http://www.nature.com/leu/)","snPcode":"41375","submissionUrl":"https://mts-leu.nature.com/cgi-bin/main.plex","title":"Leukemia","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"96adacd9-adb5-4c3e-b33e-47e6826ed5e0","owner":[],"postedDate":"May 6th, 2026","published":true,"recentEditorialEvents":[{"type":"editorInvitedReview","content":"This content is not available.","date":"2026-05-13T10:08:02+00:00","index":1,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2026-05-06T08:02:23+00:00","index":3,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2026-05-02T08:32:39+00:00","index":3,"fulltext":"This content is not available."}],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":67146107,"name":"Biological sciences/Cancer/Haematological cancer/Myeloproliferative disease"},{"id":67146108,"name":"Health sciences/Medical research"}],"tags":[],"updatedAt":"2026-05-06T10:14:11+00:00","versionOfRecord":[],"versionCreatedAt":"2026-05-06 10:14:11","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9510524","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9510524","identity":"rs-9510524","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}